

(19)



(11)

EP 3 886 847 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

02.10.2024 Bulletin 2024/40

(45) Date of publication and mention of the grant of the patent:

21.08.2024 Bulletin 2024/34

(21) Application number: **19808606.8**

(22) Date of filing: **27.11.2019**

(51) International Patent Classification (IPC):

A61K 31/4245 ^(2006.01) **A61K 31/4439** ^(2006.01)
A61K 31/426 ^(2006.01) **A61K 35/763** ^(2015.01)
A61K 45/06 ^(2006.01) **A61P 35/00** ^(2006.01)
A61K 39/12 ^(2006.01) **A61P 31/22** ^(2006.01)
C12N 7/00 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)

A61K 45/06; A61K 31/4245; A61K 31/426;
A61K 31/4439; A61K 39/12; A61P 31/22;
A61P 35/00; C12N 7/00; C12N 2710/16632;
C12N 2710/16634

(Cont.)

(86) International application number:

PCT/EP2019/082751

(87) International publication number:

WO 2020/109389 (04.06.2020 Gazette 2020/23)

(54) HELICASE PRIMASE INHIBITORS FOR TREATING CANCER IN A COMBINATION THERAPY WITH ONCOLYTIC VIRUSES

HELIKASE-PRIMASE-INHIBITOREN ZUR BEHANDLUNG VON KREBS IN EINER KOMBINATIONSTHERAPIE MIT ONKOLYTISCHE VIREN

INHIBITEURS D'HELICASE-PRIMASE POUR LE TRAITEMENT DU CANCER DANS UNE THÉRAPIE COMBINÉE AVEC DES VIRUS ONCOLYTIQUES

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **28.11.2018 EP 18208756**

(43) Date of publication of application:

06.10.2021 Bulletin 2021/40

(73) Proprietor: **Innovative Molecules GmbH**

81373 München (DE)

(72) Inventors:

- **KLEYMANN, Gerald**
32107 Bad Salzuflen (DE)
- **GEGE, Christian**
89584 Ehingen (DE)

(74) Representative: **Gille Hrabal**

Partnerschaftsgesellschaft mbB
Patentanwälte
Brucknerstraße 20
40593 Düsseldorf (DE)

(56) References cited:

WO-A1-2017/174640

- **D KOLODKIN-GAL ET AL: "Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect", GENE THERAPY, vol. 16, no. 7, 14 May 2009 (2009-05-14), GB, pages 905 - 915, XP055589479, ISSN: 0969-7128, DOI: 10.1038/gt.2009.44**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 886 847 B8

- **YAJIMA MISAKO ET AL: "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 139, 24 December 2016 (2016-12-24), pages 95 - 101, XP029901946, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2016.12.008**
- **QUENELLE DEBRAC ETAL: "Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis", ANTIVIRAL RESEARCH, vol. 149, 4 November 2017 (2017-11-04), pages 1 - 6, XP085315572, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2017.11.002**

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/4245, A61K 2300/00;

A61K 31/426, A61K 2300/00;

A61K 31/4439, A61K 2300/00;

A61K 35/763, A61K 2300/00